Myofascial pain: from Virchow's to our days
https://doi.org/10.14412/2074-2711-2014-3-75-79
Abstract
Myalgia is not a definite nosological entity and fixes the attention of neurologists, rheumatologists, and physicians in other specialties. This is first of all associated with the high incidence of chronic pain syndrome that leads to long-term disability mainly in young and middle-aged persons. One of the most common reasons for seeking advice from a therapist and neurologist is low back pain that may be due to the involvement of three key anatomical players: facet joints (arthrosis treatment should make an emphasis on hondroprotectors), intervertebral disks (in case of discopathy, clinicians tend to favor nonsteroidal anti-inflammatory drugs – NSAIDs), and a muscular frame. In this case, two thirds of patients with pain syndromes in the trunk and limbs are found to have myofascial dysfunction that is defined as impaired function of one or
other muscle, which occurs with its overload and manifests itself as muscle spasm and the presence of painful muscle infiltrations or local muscle hypertonus and trigger points in the tense muscles. Ignoring this fact gives rise to the irrational use of analgesic and anti-inflammatory drugs and further to the increase of their doses because the treatment is ineffective. Modern-day therapy for myofascial syndrome is multimodal and encompasses physiotherapic and manual procedures and the use of myorelaxants rather than NSAIDs. To prescribe myorelaxants, it is necessary to understand their mechanisms of action and the effects of different agents in this group.
About the Author
I. V. Egorov
Peoples' Friendship University of Russia
Russian Federation
Russian Federation
Moscow, Russia 6, Miklukho-Maklai St., Moscow 117198
References
1. Antie D. Nevralgia and the diseases that resemble it. London: Borenstein; 1885.
2. Dejerine J avec le collaboration de Dejerine-Klü mpke. Anatomie des centres nerveux vol. Paris: Rueff; 1895–1901.
3. Клионер ИЛ. Старческие и дегенеративные изменения в суставах и позвоночнике. Москва: Медгиз; 1962. 151 с. [Klioner IL. Starcheskie i degenerativnye izmeneniya v sustavakh i pozvonochnike [Senile and degenerate changes in joints and backbone]. Moscow: Medgiz; 1962. 151 p.]
4. Попелянский ЯЮ. Вертебральные синдромы поясничного остеохондроза. Казань: Издательство Казанского Университета; 1974. Т. 1. 282 с. [Popelyanskii YaYu. Vertebral'nye sindromy poyasnichnogo osteokhondroza [Vertebralny syndromes of lumbar osteochondrosis]. Kazan': Izdatel'stvo Kazanskogo Universiteta; 1974. Vol. 1. 282 p.]
5. Скоромец AA, Скоромец ТА, Шумилина АП. Остеохондроз дисков: новые взгляды на патогенез неврологических синдромов. Неврологический журнал. 1997;(6):53–6. [Skoromets AA, Skoromets TA, Shumilina AP. Osteochondrosis of disks: new views on pathogenesis of neurologic syndromes. Nevrologicheskii zhurnal. 1997;(6):53–6. (In Russ.)]
6. Федин АИ. Дорсопатии (классификация и диагностика). Атмосфера. Нервные болезни. 2002;(2):2–8. [Fedin AI. Dorsopatiya (classification and diagnostics). Atmosfera. Nervnye bolezni. 2002;(2):2–8. (In Russ.)]
7. Bron C, Dommerholt JD. Etiology of myofascial trigger points. Curr Pain Headache Rep. 2012 Oct;16(5):439–44. DOI: http://dx.doi.org/10.1007/s11916-012-0289-4.
8. Тревелл ДжГ, Симонс ДГ. Миофасциальные боли. Пер. с англ. Москва: Медицина; 1989. Т. 1. 240 с. [Trevell DzhG, Simons DG. Miofastsial'nye boli [Miofastsialny pains]. Translation from English. Moscow: Meditsina; 1989. Vol. 1. 240 p.]
9. Huynh AM, Aubin CE, Rajwani T, et al. Pedicle growth asymmetry as a cause of adolescent idiopathic scoliosis: a biomechanical study. Eur Spine J. 2007 Apr;16(4):523–9. DOI: http://dx.doi.org/10.1007/s00586-006-0235-4.
10. Malanga GA, Cruz Colon EJ. Myofascial low back pain: a review. Phys Med Rehabil Clin N Am. 2010 Nov;21(4):711–24. DOI: http://dx.doi.org/10.1016/j.pmr.2010.07.003.
11. Westesson KE, Shoskes DA. Chronic prostatitis/chronic pelvic pain syndrome and pelvic floor spasm: can we diagnose and treat? Curr Urol Rep. 2010 Jul;11(4):261–4. DOI: http://dx.doi.org/10.1007/s11934-010-0111-y.
12. Schmitter M, Keller L, Giannakopoulos N, et al. Chronic stress in myofascial pain patients. Clin Oral Investig. 2010 Oct;14(5):593–7. DOI: http://dx.doi.org/10.1007/s00784-009-0330-0.
13. Kuan TS. Current studies on myofascial pain syndrome. Curr Pain Headache Rep. 2009 Oct;13(5):365–9. DOI: http://dx.doi.org/10.1007/s11916-009-0059-0.
14. Partanen JV, Ojala TA, Arokoski JP. Myofascial syndrome and pain: A neurophysiological approach. Pathophysiology. 2010 Feb;17(1):19–28. DOI: http://dx.doi.org/10.1016/j.pathophys. 2009.05.001.
15. Lavelle ED, Lavelle W, Smith HS. Myofascial trigger points. Anesthesiol Clin. 2007 Dec;25(4):841–51. DOI: http://dx.doi.org/10.1016/j.anclin.2007.07.003
16. Niddam DM, Chan RC, Lee SH, et al. Central modulation of pain evoked from myofascial trigger point. Clin J Pain. 2007 Jun;23(5):440–8. DOI: http://dx.doi.org/10.1097/ AJP.0b013e318058accb.
17. Yap EC. Myofascial pain – an overview. Ann Acad Med Singapore. 2007 Jan;36(1):43–8.
18. Hong CZ. Treatment of myofascial pain syndrome. Curr Pain Headache Rep. 2006 Oct;10(5):345–9. DOI: http://dx.doi.org/10. 1007/s11916-006-0058-3.
19. Dogan SK, Evchik D, Baser OC. Comparison the efficacy of phonophoresis and ultrasound therapy in myofascial pain syndrome. Rheumatol Int. 2011 Sep;31(9):1203–8. DOI: http://dx.doi.org/10.1007/s00296-010-1419-0.
20. Carrasco TG, Guerisoli LD, Guerisoli DM, Mazzetto MO. Evaluation of low intensity laser therapy in myofascial pain syndrome. Cranio. 2009 Oct;27(4):243–7.
21. Vernon H, Schneider M. Chiropractic management of myofascial trigger points and myofascial pain syndrome: a systematic review of the literature. J Manipulative Physiol Ther. 2009 Jan;32(1):14–24. DOI: 10.1016/j.jmpt.2008.06.012.
22. Sidebottom AJ, Patel AA, Amin J. Botulinum injection for the management of myofascial pain in the masticatory muscles. A prospective outcome study. Br J Oral Maxillofac Surg. 2013 Apr;51(3):199–205.
23. Gerwin R. Botulinum toxin treatment of myofascial pain: a critical review of the literature. Curr Pain Headache Rep. 2012 Oct;16(5):413–22. DOI: http://dx.doi.org/10.1007/s11916-012-0287-6.
24. Davies J, Quinlan JE. Selective inhibition of responses of feline dorsal horn neurones to noxious cutaneous stimuli by tizanidine (DS103-282) and noradrenaline: involvement of alpha 2-adrenoceptors. Neurosci. 1985;16(3):673–76. DOI: http://dx.doi.org/10.1016/0306- 4522(85)90200-3.
25. Maeda-Hagiwara M, Watanabe H, Kanaoka R, Watanabe K. Reduction of centrally-stimulated gastric acid secretion by tizanidine, a new imidazoline derivative, in anesthetized rats. Arch Int Pharmacodyn Ther. 1985;277(2):321–7.
26. Berry H, Hutchinson DR. Tizanidine and ibuprofen in acute low-back pain: Results of a double-blind multicentre study in general practice. J Int Med Res. 1988;16(2):83–91.
27. Данилов АБ. Возможности применения тизанидина в клинической практике. Русский медицинский журнал. 2009;17(20):1370–6. [Danilov AB. Possibilities of application of a tizanidin in clinical practice. Russkii meditsinskii zhurnal. 2009;17(20):1370–6. (In Russ.)]
28. Pohjolainen T, Jekunen A, Autio L, Vuorela H. Treatment of acute low back pain with the COX-2-selective anti-inflammatory drug nimesulide: results of a randomized, double-blind comparative trial versus ibuprofen. Spine (Phila Pa 1976). 2000;25(12):579–85. DOI: http://dx.doi.org/10.1097/00007632-
29. -00019.
30. Ilic K, Sefik M, Jankovic S. Efficacy and safety of two generic copies of nimesulide in patients with low back pain or knee osteoarthritis. Reumatismo. 2009;61(1):27–33.
31. Suleyman H, Cadirci E, Albayrak A. Nimesulide is a selective COX-2 inhibitory, atypical non-steroidal anti-inflammatory drug. Curr Med Chem. 2008;15:278–83. DOI: http://dx.doi.org/10.2174/092986708783497247.
32. Marcolongo R, Frediani B, Biasi G, et al. A meta-analysis of the tolerability of amtolmetin guacil, a novel, effective nonsteroidal antiinflammatory drug, compared with established agents. Clin Drug Invest. 1999 Feb;17(2):89–96. DOI: http://dx.doi.org/10.2165/00044011- 199917020-00002.
33. Егоров ИВ. Найзилат – новый НПВП с эффективностью диклофенака и безопасностью коксибов. Поликлиника. 2013;(4):66-7. [Egorov IV. Nayzilat – new NPVP with efficiency of diclofenac and safety koksibov. Poliklinika. 2013;(4):66–7. (In Russ.)]
34. Coruzzi G, Coppelli G, Spaggiari S, et al. Gastroprotective effects of amtolmetin guacyl: a new non-steroidal anti-inflammatory drug that activates inducible gastric nitric oxide synthase. Dig Liver Dis. 2002 Jun;34(6):403–10. DOI: http://dx.doi.org/10.1016/S1590- 8658(02)80037-8.
Review
Views: 3906
Email this article 